EA201700177A1 - Улучшенный способ конъюгирования и полученные с помощью него новые синтетические конъюгаты олигосахарида с белком - Google Patents

Улучшенный способ конъюгирования и полученные с помощью него новые синтетические конъюгаты олигосахарида с белком

Info

Publication number
EA201700177A1
EA201700177A1 EA201700177A EA201700177A EA201700177A1 EA 201700177 A1 EA201700177 A1 EA 201700177A1 EA 201700177 A EA201700177 A EA 201700177A EA 201700177 A EA201700177 A EA 201700177A EA 201700177 A1 EA201700177 A1 EA 201700177A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oligosaccharide
protein
synthetic
conjugates
conjugation
Prior art date
Application number
EA201700177A
Other languages
English (en)
Inventor
Девиндер Джилл
Манодж Кумар Чхикара
Ракеш Рана
Джунед Далал
Дипти Сингх
Original Assignee
Мсд Уэлком Траст Хиллеман Лабораторис Пвт. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мсд Уэлком Траст Хиллеман Лабораторис Пвт. Лтд. filed Critical Мсд Уэлком Траст Хиллеман Лабораторис Пвт. Лтд.
Publication of EA201700177A1 publication Critical patent/EA201700177A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к улучшенному способу конъюгирования для получения синтетических конъюгатов олигосахарида с белком (OS-PR). Способ синтетического конъюгирования OS-PR представляет собой быстрый способ, обеспечивающий конъюгаты олигосахарида с белком, которые являются высокоиммуногенными и вызывают специфические и однородные иммунные ответы. Синтетический олигосахарид содержит четыре-восемь повторяющихся структурных единиц соответствующих мономеров и по меньшей мере один встроенный концевой аминный линкер, причем указанный синтетический полисахарид имитирует природный полисахарид, полученный из таких грамотрицательных бактерий, как серогруппы А, С, Y, W, X Neisseria meningitidis и Haemophilus influenza, и белок-носитель получен из таких грамположительных бактерий, как Clostridium tetani (столбнячный анатоксин) или Corynebacterium diphtheriae (CRM197) или их рекомбинантных вариантов. Химия конъюгирования указанного конъюгата олигосахарида с белком согласно настоящему изобретению представляет собой тиоэфирную связь. Настоящее изобретение предусматривает полное время проведения способа в диапазоне 14-22 ч. Указанные конъюгаты олигосахарида с белком являются применимыми в получении моновалентной вакцины или мультивалентных комбинированных вакцин и в качестве диагностического средства.
EA201700177A 2014-10-09 2015-10-08 Улучшенный способ конъюгирования и полученные с помощью него новые синтетические конъюгаты олигосахарида с белком EA201700177A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2884DE2014 2014-10-09
PCT/IB2015/057682 WO2016055957A1 (en) 2014-10-09 2015-10-08 An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof

Publications (1)

Publication Number Publication Date
EA201700177A1 true EA201700177A1 (ru) 2017-07-31

Family

ID=55652678

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201700177A EA201700177A1 (ru) 2014-10-09 2015-10-08 Улучшенный способ конъюгирования и полученные с помощью него новые синтетические конъюгаты олигосахарида с белком

Country Status (18)

Country Link
US (1) US10105438B2 (ru)
EP (1) EP3204396A4 (ru)
JP (1) JP2017531662A (ru)
KR (1) KR20170065030A (ru)
CN (1) CN106795194A (ru)
AU (1) AU2015329590B2 (ru)
BR (1) BR112017006447A2 (ru)
CA (1) CA2963900A1 (ru)
CL (1) CL2017000844A1 (ru)
CO (1) CO2017003291A2 (ru)
CU (1) CU20170046A7 (ru)
EA (1) EA201700177A1 (ru)
IL (1) IL251511A0 (ru)
MX (1) MX2017004495A (ru)
PH (1) PH12017500579A1 (ru)
SG (1) SG11201702451WA (ru)
TN (1) TN2017000126A1 (ru)
WO (1) WO2016055957A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170198004A1 (en) * 2014-05-24 2017-07-13 Biological E Limited Novel semi-synthetic meningococcal conjugate vaccine
WO2017017509A1 (en) * 2015-07-28 2017-02-02 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel neisseria meningitidis serogroup y oligomer and process for synthesizing thereof
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
KR102634811B1 (ko) 2017-06-10 2024-02-06 인벤트프라이즈 인크. 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3094406C (en) * 2018-03-23 2024-05-14 Koranex Capital Precision glycoconjugates as therapeutic tools
CN113274488B (zh) * 2021-04-30 2023-08-29 山东省药学科学院 一种特异性预防真菌感染的寡糖疫苗及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434668A1 (en) * 2003-07-04 2005-01-04 Laurence Mulard Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a
AU2006245440B2 (en) * 2005-05-06 2012-04-19 Novartis Vaccines And Diagnostics Srl Immunogens for meningitidis-A vaccines
FR2904627B1 (fr) * 2006-08-04 2008-11-07 Pasteur Institut Nouveaux peptides actives, purifies et isoles, derives du recepteur cd4 (mini-cd4) et leur procece de preparation
RU2013131795A (ru) * 2010-12-10 2015-01-20 Мерк Шарп Энд Домэ Корп. Новые композиции, которые уменьшают вызываемую встряхиванием агрегацию иммуногенных композиций
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process

Also Published As

Publication number Publication date
BR112017006447A2 (pt) 2017-12-12
CA2963900A1 (en) 2016-04-14
MX2017004495A (es) 2017-12-18
CL2017000844A1 (es) 2017-12-22
CN106795194A (zh) 2017-05-31
TN2017000126A1 (en) 2018-10-19
SG11201702451WA (en) 2017-04-27
US10105438B2 (en) 2018-10-23
PH12017500579A1 (en) 2017-08-30
AU2015329590B2 (en) 2019-08-22
US20170246313A1 (en) 2017-08-31
IL251511A0 (en) 2017-05-29
CU20170046A7 (es) 2017-06-05
JP2017531662A (ja) 2017-10-26
WO2016055957A1 (en) 2016-04-14
EP3204396A1 (en) 2017-08-16
CO2017003291A2 (es) 2017-06-30
KR20170065030A (ko) 2017-06-12
AU2015329590A1 (en) 2017-05-04
EP3204396A4 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
EA201700177A1 (ru) Улучшенный способ конъюгирования и полученные с помощью него новые синтетические конъюгаты олигосахарида с белком
PE20220774A1 (es) Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos
MX2020002558A (es) Procesos para la formulacion de polisacaridos neumococicos para la conjugacion a una proteina transportadora.
PH12019501552A1 (en) Polypeptide-antigen conjugates with non-natural amino acids
PE20161095A1 (es) Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos
BR112020004502A8 (pt) Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
BR112020004471A8 (pt) Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
BR112019001995A2 (pt) composição de conjugado de polissacarídeo pneumocócico multivalente ? proteína
IN2014DN09791A (ru)
MX2018004939A (es) Vacuna.
AR090294A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
MX2018010920A (es) Nuevos conjugados de polisacarido-proteina, y procedimiento para obtener los mismos.
BRPI0607551A2 (pt) vacinas de combinação de helicobacter e circovìrus porcino e métodos de uso
RU2014134288A (ru) Иммуногенная композиция
PH12016500360A1 (en) A bacterial vaccine and methods for manufacture thereof
MX2015002483A (es) Composiciones inmunogenicas.
MY183392A (en) Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
MX337202B (es) Vacunas de conjugado carbohidrato-glicolipido.
CY1123600T1 (el) Μεθοδος θεραπειας
BR112019003419A2 (pt) composição de vacina multivalente
EP3804749A3 (en) Antigens and antigen combinations
TH179730A (th) กระบวนการที่ได้รับการปรับปรุงของการคอนจูเกต (คอนจูเกต) และคอนจูเกต สังเคราะห์ชนิดใหม่ของโอลิโกแซคคาไลด์-โปรตีนที่ได้มาของสารเหล่านี้
BR112018001425A2 (pt) novos oligômeros de sorogrupo y de neisseria meningitidis e processos de sintetização dos mesmos
IN2014MU00349A (ru)
AR120233A1 (es) Proceso de producción, recuperación y purificación de polisacárido capsular polirribosil ribitol fosfato (prp) y uso del mismo